Evotec stock at EUR 2.56 ahead of the Xetra open: drug discovery group slightly lower
Published on 10/19/2026 at 07:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness model and market context
- Evotec uses data, science and artificial intelligence with partners to develop medicines.
- Germany's DAX is the benchmark for Evotec's home market.
- Evotec stock trades pre-market at EUR 2.56 at 7:39 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.39 percent below the Xetra close of October 16, 2026.
Evotec develops and advances medicines with partners by combining molecular patient data, disease models, omics-based research and artificial-intelligence technologies, generating revenue through collaborations, milestones, licenses and royalties. Evotec Investor Relations describes these activities.
Evotec stock trades pre-market at EUR 2.56 at 7:39 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.39 percent below the Xetra close of October 16, 2026 (EUR 2.57).
Ahead of the Xetra open
The pre-market indication is EUR 0.01 below the Xetra close. Bid EUR 2.53 and ask EUR 2.59 imply a 2.34 percent spread, indicating thin pre-market trading. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Evotec stock.
How Evotec earns revenue
Evotec's business model combines drug-discovery research and development services with partner collaborations, milestone payments, licenses and potential royalties. Market context: Market report DAX.
